Sectoral Asset Management Inc.
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 14, 2024), Sectoral Asset Management Inc. reported 92 stock positions worth $254.4 million. Its top holding was Lenz Therapeutics (LENZ) at 9.4% of the portfolio, followed by Eli Lilly (LLY, 7.8%) and Boundless Bio (BOLD, 4.8%). Compared with Q4 2023, it opened 14 new positions, sold out of 26, added to 25 and reduced 49. The biggest buy was a new position in Lenz Therapeutics (LENZ) and the biggest sale Amgen (AMGN, shares −44%).
- Most Recent 13F
- Q2 2026
- Location
- MONTREAL, A8
- CIK
- 0001274413
- Portfolio Value
- $254.4M (Q1 2024)
- SEC Filing
- 0001104659-24-061089 ↗ filed May 14, 2024
Holdings Value
Holdings 92 stocks · $254.4M
| LENZ Lenz Therapeutics Inc. | 9.38% | 1,068,675 | $23.9M | New |
| LLY Eli Lilly & Co. | 7.85% | 25,665 | $20.0M | Reduce -3.4% |
| BOLD Boundless Bio Inc. | 4.79% | 855,875 | $12.2M | New |
| UNH Unitedhealth Group Inc. | 4.51% | 23,175 | $11.5M | Add +22.5% |
| MRK Merck & Co. Inc. | 4.49% | 86,500 | $11.4M | Add +8.8% |
| ABT Abbott Laboratories | 3.14% | 70,248 | $8.0M | Add +1.8% |
| JNJ Johnson & Johnson | 2.98% | 47,850 | $7.6M | Reduce -11.1% |
| MLYS Mineralys Therapeutics Inc. | 2.80% | 552,256 | $7.1M | Reduce -8.8% |
| REGN Regeneron Pharmaceuticals | 2.68% | 7,075 | $6.8M | Add +84.5% |
| ABBV Abbvie Inc. | 2.52% | 35,200 | $6.4M | Reduce -24.0% |
| BSX Boston Scientific Corp. | 2.33% | 86,476 | $5.9M | Reduce -5.5% |
| TMO Thermo Fisher Scientific Inc. | 2.29% | 10,015 | $5.8M | Add +11.1% |
| PFE Pfizer Inc. | 2.07% | 189,400 | $5.3M | No change |
| AMGN Amgen Inc. | 1.80% | 16,085 | $4.6M | Reduce -43.9% |
| BMRN Biomarin Pharmaceutical Inc. | 1.77% | 51,640 | $4.5M | Add +3.1% |
| DXCM Dexcom Inc. | 1.77% | 32,400 | $4.5M | Add +10.2% |
| DHR Danaher Corp. | 1.74% | 17,725 | $4.4M | Add +18.4% |
| ZBH Zimmer Biomet Holdings Inc. | 1.54% | 29,750 | $3.9M | New |
| ARGX Argenx SE - ADR | 1.44% | 9,307 | $3.7M | Reduce -7.2% |
| IQV Iqvia Holdings Inc. | 1.40% | 14,100 | $3.6M | Reduce -15.1% |
| MDT Medtronic PLC | 1.30% | 38,051 | $3.3M | Reduce -5.0% |
| PODD Insulet Corp. | 1.22% | 18,100 | $3.1M | Add +39.8% |
| VRTX Vertex Pharmaceuticals Inc. | 1.18% | 7,210 | $3.0M | Reduce -21.8% |
| CYTK Cytokinetics Inc. | 1.17% | 42,583 | $3.0M | Add +507.2% |
| PGNY Progyny Inc. | 1.14% | 76,000 | $2.9M | New |
| GILD Gilead Sciences Inc. | 1.11% | 38,705 | $2.8M | Reduce -5.4% |
| ALNY Alnylam Pharmaceuticals Inc. | 1.08% | 18,460 | $2.8M | Reduce -18.5% |
| ICLR Icon PLC | 1.05% | 7,943 | $2.7M | Reduce -22.1% |
| CNC Centene Corp. | 1.05% | 34,000 | $2.7M | New |
| FOLD Amicus Therapeutics Inc. | 1.02% | 221,044 | $2.6M | Add +41.0% |
| NARI Inari Medical Inc. | 0.99% | 52,500 | $2.5M | New |
| ISRG Intuitive Surgical Inc. | 0.96% | 6,100 | $2.4M | New |
| SYK Stryker Corp. | 0.93% | 6,600 | $2.4M | New |
| MLTX Moonlake Immunotherapeutics | 0.91% | 46,295 | $2.3M | Add +54.3% |
| GDRX Goodrx Holdings Inc. Class A | 0.90% | 321,000 | $2.3M | Reduce -11.8% |
| SRPT Sarepta Therapeutics Inc. | 0.88% | 17,291 | $2.2M | Reduce -19.7% |
| OPCH Option Care Health Inc. | 0.84% | 64,000 | $2.1M | No change |
| SPRY Ars Pharmaceuticals Inc. | 0.82% | 204,437 | $2.1M | Reduce -42.4% |
| ARVN Arvinas Inc. | 0.79% | 48,780 | $2.0M | Reduce -26.1% |
| VERA Vera Therapeutics Inc. | 0.76% | 44,901 | $1.9M | Reduce -63.8% |
| EYPT Eyepoint Inc. | 0.75% | 92,340 | $1.9M | Add +13.8% |
| ATEC Alphatec Holdings Inc. | 0.74% | 136,000 | $1.9M | New |
| ITOS Iteos Therapeutics Inc. | 0.72% | 133,966 | $1.8M | Reduce -39.1% |
| ELV Elevance Health Inc. | 0.71% | 3,500 | $1.8M | New |
| COGT Cogent Biosciences Inc. | 0.70% | 263,700 | $1.8M | New |
| RCUS Arcus Biosciences Inc. | 0.69% | 93,635 | $1.8M | Reduce -3.9% |
| AZN Astrazeneca PLC-Spons ADR | 0.65% | 24,430 | $1.7M | Reduce -6.5% |
| HUM Humana Inc. | 0.65% | 4,751 | $1.6M | Reduce -42.2% |
| SLRN Acelyrin Inc. | 0.65% | 244,000 | $1.6M | Reduce -25.1% |
| OLMA Olema Pharmaceuticals Inc. | 0.62% | 139,980 | $1.6M | Add +627.9% |
| MRNA Moderna Inc. | 0.62% | 14,740 | $1.6M | Reduce -8.4% |
| BIIB Biogen Inc. | 0.59% | 6,967 | $1.5M | Reduce -56.0% |
| EW Edwards Lifesciences Corp. | 0.59% | 15,650 | $1.5M | Reduce -28.5% |
| EFTR Effector Therapeutics Inc. | 0.54% | 95,305 | $1.4M | New |
| TSBX Turnstone Biologics Corp. | 0.53% | 517,648 | $1.4M | No change |
| SMMT Summit Therapeutics Inc. | 0.51% | 315,000 | $1.3M | Add +950.0% |
| ALT Altimmune Inc. | 0.37% | 92,240 | $939K | Reduce -46.0% |
| VSTM Verastem Inc. | 0.34% | 74,200 | $876K | Reduce -63.5% |
| ILMN Illumina Inc. | 0.34% | 6,280 | $862K | Reduce -4.8% |
| SNY Sanofi-ADR | 0.24% | 12,670 | $616K | Reduce -10.1% |
| ASND Ascendis Pharma A/S | 0.24% | 4,011 | $606K | Reduce -9.7% |
| UTHR United Therapeutics Corp. | 0.23% | 2,595 | $596K | Reduce -7.8% |
| RPRX Royalty Pharma PLC Class A | 0.23% | 19,420 | $590K | Reduce -5.6% |
| PCVX Vaxcyte Inc. | 0.23% | 8,500 | $581K | Add +5.6% |
| NBIX Neurocrine Biosciences Inc. | 0.23% | 4,195 | $579K | Reduce -5.6% |
| ONC Beone Medicines Ltd.-ADR filed as BEIGENE LTD | 0.23% | 3,692 | $577K | Reduce -1.6% |
| APLS Apellis Pharmaceuticals Inc. | 0.22% | 9,670 | $568K | Add +85.3% |
| INCY Incyte Corp. | 0.21% | 9,405 | $536K | Reduce -6.9% |
| MEDP Medpace Holdings Inc. | 0.21% | 1,291 | $522K | Reduce -5.8% |
| ROIV Roivant Sciences Ltd. | 0.20% | 49,457 | $521K | Add +35.7% |
| BBIO Bridgebio Pharma Inc. | 0.20% | 16,105 | $498K | Add +24.3% |
| ITCI Intra-Cellular Therapies Inc. | 0.19% | 7,080 | $490K | Reduce -4.6% |
| JAZZ Jazz Pharmaceuticals PLC | 0.18% | 3,894 | $469K | Reduce -4.9% |
| INSM Insmed Inc. | 0.18% | 16,421 | $446K | Add +18.9% |
| IONS Ionis Pharmaceuticals Inc. | 0.17% | 10,100 | $438K | Add +55.9% |
| BPMC Blueprint Medicines Corp. | 0.16% | 4,410 | $418K | Add +78.5% |
| RVMD Revolution Medicines Inc. | 0.16% | 12,910 | $416K | Reduce -5.8% |
| RDY Dr. Reddy's Laboratories-ADR | 0.16% | 5,500 | $403K | Add +22.2% |
| RCKT Rocket Pharmaceuticals Inc. | 0.16% | 14,810 | $399K | Add +20.6% |
| ALKS Alkermes PLC | 0.15% | 14,230 | $385K | Reduce -7.2% |
| BNTX Biontech SE-ADR | 0.13% | 3,525 | $325K | Reduce -5.4% |
| EXEL Exelixis Inc. | 0.12% | 13,140 | $312K | Reduce -6.1% |
| MDGL Madrigal Pharmaceuticals Inc. | 0.12% | 1,131 | $302K | Reduce -5.8% |
| SRRK Scholar Rock Holding Corp. | 0.11% | 15,400 | $274K | New |
| GPCR Structure Therapeutics Inc. | 0.10% | 5,964 | $256K | Add +75.4% |
| DNLI Denali Therapeutics Inc. | 0.10% | 12,081 | $248K | Reduce -6.2% |
| NTLA Intellia Therapeutics Inc. | 0.10% | 8,800 | $242K | Reduce -5.4% |
| HALO Halozyme Therapeutics Inc. | 0.09% | 5,680 | $231K | Reduce -5.8% |
| ARWR Arrowhead Pharmaceuticals Inc. | 0.09% | 7,682 | $220K | Reduce -6.1% |
| KYTX Kyverna Therapeutics Inc. | 0.07% | 7,000 | $174K | New |
| LEGN Legend Biotech Corp.-ADR | 0.07% | 3,000 | $168K | No change |
| ZLAB Zai Lab Ltd.-ADR | 0.01% | 2,000 | $32K | Reduce -50.0% |
Portfolio Sells Q4 2023 → Q1 2024
| AMGN Amgen Inc. | Reduce -43.9% | 1.80% | −1.76 |
| EWTX Edgewise Therapeutics Inc. | Sold out | 0.00% | −1.54 |
| ANNX Annexon Inc. | Sold out | 0.00% | −1.27 |
| FDMT 4D Molecular Therapeutics Inc. | Sold out | 0.00% | −1.24 |
| BIIB Biogen Inc. | Reduce -56.0% | 0.59% | −1.17 |
| STRO Sutro Biopharma Inc. Com SHS | Sold out | 0.00% | −1.15 |
| REPL Replimune Group Inc. | Sold out | 0.00% | −1.11 |
| TVTX Travere Therapeutics Inc. | Sold out | 0.00% | −1.06 |
| HUM Humana Inc. | Reduce -42.2% | 0.65% | −0.97 |
| PMVP PMV Pharmaceuticals Inc. | Sold out | 0.00% | −0.92 |
| PRVA Privia Health Group Inc. | Sold out | 0.00% | −0.90 |
| ALLK Allakos LLC | Sold out | 0.00% | −0.88 |
| AXONICS INC | Sold out | 0.00% | −0.88 |
| SNDX Syndax Pharmaceuticals Inc. | Sold out | 0.00% | −0.86 |
| CNMD Conmed Corp. | Sold out | 0.00% | −0.85 |
| QURE Uniqure NV | Sold out | 0.00% | −0.85 |
| XBI SS SPDR S&P Biotech ETF | Sold out | 0.00% | −0.79 |
| ALNY Alnylam Pharmaceuticals Inc. | Reduce -18.5% | 1.08% | −0.78 |
| BCAB Bioatla Inc. | Sold out | 0.00% | −0.75 |
| PRTA Prothena Corp. PLC | Sold out | 0.00% | −0.73 |
| IOVA Iovance Biotherapeutics Inc. | Sold out | 0.00% | −0.70 |
| JNJ Johnson & Johnson | Reduce -11.1% | 2.98% | −0.66 |
| ABBV Abbvie Inc. | Reduce -24.0% | 2.52% | −0.57 |
| AMLX Amylyx Pharmaceuticals Inc. | Sold out | 0.00% | −0.53 |
| GRPH Graphite Bio Inc. | Sold out | 0.00% | −0.50 |
| EFFECTOR THERAPEUTICS INC | Sold out | 0.00% | −0.48 |
| ALT Altimmune Inc. | Reduce -46.0% | 0.37% | −0.46 |
| VRTX Vertex Pharmaceuticals Inc. | Reduce -21.8% | 1.18% | −0.43 |
| SLRN Acelyrin Inc. | Reduce -25.1% | 0.65% | −0.40 |
| ARVN Arvinas Inc. | Reduce -26.1% | 0.79% | −0.38 |
| VSTM Verastem Inc. | Reduce -63.5% | 0.34% | −0.37 |
| ITOS Iteos Therapeutics Inc. | Reduce -39.1% | 0.72% | −0.32 |
| GILD Gilead Sciences Inc. | Reduce -5.4% | 1.11% | −0.31 |
| KRTX Karuna Therapeutics Inc. | Sold out | 0.00% | −0.30 |
| IQV Iqvia Holdings Inc. | Reduce -15.1% | 1.40% | −0.25 |
| FUSN Fusion Pharmaceuticals Inc. | Sold out | 0.00% | −0.24 |
| IMGN Immunogen Inc. | Sold out | 0.00% | −0.23 |
| ACAD Acadia Pharmaceuticals Inc. | Sold out | 0.00% | −0.20 |
| ARGX Argenx SE - ADR | Reduce -7.2% | 1.44% | −0.20 |
| ICLR Icon PLC | Reduce -22.1% | 1.05% | −0.19 |
| MRTX Mirati Therapeutics Inc. | Sold out | 0.00% | −0.16 |
| GDRX Goodrx Holdings Inc. Class A | Reduce -11.8% | 0.90% | −0.15 |
| EW Edwards Lifesciences Corp. | Reduce -28.5% | 0.59% | −0.13 |
| MDT Medtronic PLC | Reduce -5.0% | 1.30% | −0.12 |
| AZN Astrazeneca PLC-Spons ADR | Reduce -6.5% | 0.65% | −0.11 |
| RCUS Arcus Biosciences Inc. | Reduce -3.9% | 0.69% | −0.11 |
| MRNA Moderna Inc. | Reduce -8.4% | 0.62% | −0.07 |
| ONC Beone Medicines Ltd.-ADR | Reduce -1.6% | 0.23% | −0.06 |
| INCY Incyte Corp. | Reduce -6.9% | 0.21% | −0.06 |
| VERA Vera Therapeutics Inc. | Reduce -63.8% | 0.76% | −0.06 |
Portfolio Buys Q4 2023 → Q1 2024
| LENZ Lenz Therapeutics Inc. | New | 9.38% | +9.38 |
| BOLD Boundless Bio Inc. | New | 4.79% | +4.79 |
| ZBH Zimmer Biomet Holdings Inc. | New | 1.54% | +1.54 |
| REGN Regeneron Pharmaceuticals | Add +84.5% | 2.68% | +1.23 |
| PGNY Progyny Inc. | New | 1.14% | +1.14 |
| CNC Centene Corp. | New | 1.05% | +1.05 |
| NARI Inari Medical Inc. | New | 0.99% | +0.99 |
| ISRG Intuitive Surgical Inc. | New | 0.96% | +0.96 |
| SYK Stryker Corp. | New | 0.93% | +0.93 |
| CYTK Cytokinetics Inc. | Add +507.2% | 1.17% | +0.92 |
| MRK Merck & Co. Inc. | Add +8.8% | 4.49% | +0.75 |
| ATEC Alphatec Holdings Inc. | New | 0.74% | +0.74 |
| ELV Elevance Health Inc. | New | 0.71% | +0.71 |
| COGT Cogent Biosciences Inc. | New | 0.70% | +0.70 |
| EFTR Effector Therapeutics Inc. | New | 0.54% | +0.54 |
| OLMA Olema Pharmaceuticals Inc. | Add +627.9% | 0.62% | +0.51 |
| SMMT Summit Therapeutics Inc. | Add +950.0% | 0.51% | +0.48 |
| DHR Danaher Corp. | Add +18.4% | 1.74% | +0.25 |
| TMO Thermo Fisher Scientific Inc. | Add +11.1% | 2.29% | +0.23 |
| UNH Unitedhealth Group Inc. | Add +22.5% | 4.51% | +0.22 |
| DXCM Dexcom Inc. | Add +10.2% | 1.77% | +0.20 |
| MLTX Moonlake Immunotherapeutics | Add +54.3% | 0.91% | +0.13 |
| SRRK Scholar Rock Holding Corp. | New | 0.11% | +0.11 |
| APLS Apellis Pharmaceuticals Inc. | Add +85.3% | 0.22% | +0.09 |
| KYTX Kyverna Therapeutics Inc. | New | 0.07% | +0.07 |
| BPMC Blueprint Medicines Corp. | Add +78.5% | 0.16% | +0.07 |
| FOLD Amicus Therapeutics Inc. | Add +41.0% | 1.02% | +0.07 |
| GPCR Structure Therapeutics Inc. | Add +75.4% | 0.10% | +0.04 |
| IONS Ionis Pharmaceuticals Inc. | Add +55.9% | 0.17% | +0.03 |
| ROIV Roivant Sciences Ltd. | Add +35.7% | 0.20% | +0.03 |
| RDY Dr. Reddy's Laboratories-ADR | Add +22.2% | 0.16% | +0.02 |
| PCVX Vaxcyte Inc. | Add +5.6% | 0.23% | +0.01 |
| PODD Insulet Corp. | Add +39.8% | 1.22% | +0.01 |
| RCKT Rocket Pharmaceuticals Inc. | Add +20.6% | 0.16% | −0.00 |
| INSM Insmed Inc. | Add +18.9% | 0.18% | −0.01 |
| BBIO Bridgebio Pharma Inc. | Add +24.3% | 0.20% | −0.03 |
| EYPT Eyepoint Inc. | Add +13.8% | 0.75% | −0.06 |
| ABT Abbott Laboratories | Add +1.8% | 3.14% | −0.13 |
| BMRN Biomarin Pharmaceutical Inc. | Add +3.1% | 1.77% | −0.31 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 82 | $143.3M | CTNM, SI, LLY, UNH, JNJ |
| Q1 2026 | 77 | $120.7M | EVMN, CTNM, SI, LLY, JNJ |
| Q4 2025 | 74 | $124.8M | EVMN, CTNM, LLY, SI, UNH |
| Q3 2025 | 82 | $162.0M | CTNM, LLY, GPCR, ANAB, SI |
| Q2 2025 | 94 | $151.5M | LENZ, LLY, UNH, MLYS, CTNM |
| Q1 2025 | 84 | $128.5M | LENZ, LLY, UNH, MLYS, CTNM |
| Q4 2024 | 86 | $149.8M | LENZ, CTNM, LLY, UNH, GILD |
| Q3 2024 | 90 | $169.3M | LENZ, CTNM, LLY, UNH, GILD |
| Q2 2024 | 97 | $246.1M | LLY, LENZ, CTNM, UNH, MRK |
| Q1 2024 | 92 | $254.4M | LENZ, LLY, BOLD, UNH, MRK |